What disease is ixazomib used to treat?

Ixazomib is used to treat multiple myeloma, a malignant tumor that originates from plasma cells in the bone marrow. Ixazomib was developed by Takeda Pharmaceutical Company and was first approved for marketing in the United States on November 20, 2015.

Ixazomib is used in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The recommended starting dose of ixazomib is 1, 8 and 15 days, 1 times a week, 4 mg orally administered each time. The specific usage and dosage must be based on the guidance of a doctor and under the supervision of a doctor with experience in treating multiple myeloma.

Ixazomib is a reversible proteasome inhibitor that blocks the normal metabolism and decomposition mechanism of cancer cells and induces cancer cell apoptosis by inhibiting the proteasome function in cells. This mechanism of action allows ixazomib to show significant efficacy in the treatment of multiple myeloma.

Multiple clinical studies have confirmed the effectiveness of ixazomib combined with lenalidomide and dexamethasone in the treatment of multiple myeloma. For example, a phase III randomized double-blind clinical study that included 722 patients with relapsed, refractory or relapsed and refractory multiple myeloma showed that the median progression-free survival in the ixazomib combination treatment group was approximately 20 months and the overall response rate was as high as 78.3%.

Patients should closely monitor adverse reactions, such as diarrhea, thrombocytopenia, neutropenia, etc., while using ixazomib, and adjust the treatment plan according to the guidance of their doctor. At the same time, patients with symptoms such as allergies, severe infection, fever, and gastrointestinal bleeding should use it with caution. Common adverse reactions of ixazomib include diarrhea, thrombocytopenia, neutropenia, constipation, peripheral neuropathy, etc. If patients experience discomfort during use, they should seek medical advice promptly and inform the doctor.